Problem

BBy addresses the hospital and neonatal intensive care unit (NICU) problem of storing, thawing, and administering donor breast milk. Hospitals have traditionally kept milk frozen, creating a slow, labor-intensive workflow involving large freezers, defrosting, electricity consumption, spillage, and the risk of confusion or near misses. The killer use case is the NICU, where BBy says a nurse may spend an entire shift overseeing milk preparation instead of providing direct infant care. BBy estimates that U.S. hospitals spend $12 billion annually obtaining and managing breast milk, at a cost of roughly $9–$15 per ounce, while claiming its approach can save hospitals millions of dollars per month in labor costs.

Product / Service

BBy offers a hospital-focused breast-milk condensing system, centered on its BBy Condenser and the first device it calls “Krrish.” The process removes unbound water and converts human milk into a shelf-stable powder while using an algorithm and laser to monitor weight and temperature and keep the product within a bioactive-retention zone. BBy says the resulting powder retains the milk’s nutritional, immune, and biological properties and can be reconstituted 1:1 with water.

The operating model combines regional processing with recurring delivery to hospitals. BBy has described packaging the condensed milk in individual one- and two-ounce aluminum packets and delivering it to NICUs on a two-week cycle; nurses mix only the amount needed for a feeding. This eliminates thawing, reduces waste and freezer dependence, simplifies administration, and returns nursing time to patient care. The company reported operating eight regional processing facilities near 17 client hospitals in May 2023.

Market

BBy competes in hospital healthtech and the human-milk-processing market, specifically NICU nutrition, donor-milk logistics, and shelf-stable breast-milk storage. Its primary substitute is the entrenched frozen-storage and thawing workflow. Named competitors or adjacent alternatives include Prolacta and LactaLogics in the for-profit human-milk industry, NeoLacta and NeoKare in shelf-stable products, and Milkify, Harmony Baby Nutrition, and Group B Labs in the broader breast-milk processing and preservation landscape. These companies are not all identical substitutes: some focus on donor milk or hospital nutrition, while others focus on consumer milk preservation.

BBy appears to have moved beyond the pre-revenue concept stage, based on its disclosed client hospitals, processing facilities, and $3 million seed round led by Pioneer Fund, with additional investment from Y Combinator, 7G BioVentures, Cathexis Ventures, and angels. However, the evidence available here does not disclose revenue, pricing, regulatory milestones, or newer deployment figures after the May 2023 announcement, so its latest verifiable position is an early commercial healthtech company with meaningful but not recently updated hospital traction.